阿立哌唑：一种用于治疗精神分裂症的多巴胺部分激动剂的药效学
Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
作者信息
Gründer G, Kungel M, Ebrecht M, Göröcs T, Modell S
机构信息
Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Aachen, RWTH Aachen, Germany.
出版信息
Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S21-5. doi: 10.1055/s-2006-931485.
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
阿立哌唑是首个获批的非典型抗精神病药物，其作用机制是对多巴胺D2受体和5-羟色胺5-HT1A受体具有高亲和力的部分激动作用，同时对5-羟色胺5-HT2A受体具有拮抗作用。阿立哌唑具有良好的临床疗效以及良好的安全性和耐受性。本文将描述阿立哌唑特殊的药效学特性。
Zotero 插件